Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature

Mathew Thomas 1, Ali Wazir 2, Aarati Poudel 3

1. Internal Medicine, State University of New York Upstate Medical University, Syracuse, USA  2. Oncology, State University of New York Upstate Medical University, Syracuse, USA  3. Hematology and Oncology, Syracuse Veterans Affairs Medical Center, Syracuse, USA

Corresponding author: Mathew Thomas, mathewbthomas@gmail.com

Abstract
The development of immune checkpoint inhibitors is considered to be one of the most important advances in cancer treatment. Pembrolizumab is an immune checkpoint inhibitor against programmed death-ligand 1 (PD-L1) receptor that has demonstrated antineoplastic activity against various malignancies including non-small cell lung cancer, melanoma, and triple-negative breast cancer. Pembrolizumab has been associated with significant dermatological adverse reactions, referred to as immune-related adverse events. The cutaneous adverse effects can affect the quality of life of the patient and can result in dose reduction or even discontinuation of the treatment. Hence it is of utmost importance to have a comprehensive understanding of the cutaneous toxicities for prompt initiation of treatment.

We present the case of a 49-year-old male with metastatic non-small cell lung cancer (NSCLC) with 100% PD-L1 expression, who suffered a severe cutaneous reaction involving more than 95% of body surface area, following the first dose of pembrolizumab. He was treated with low-dose systemic steroids (prednisone 10 mg), to which he responded well. Since the patient showed excellent symptomatic and clinical response to pembrolizumab, it was not discontinued. The patient has not developed a rash with subsequent doses of pembrolizumab, and the steroids were tapered off.

Introduction
Pembrolizumab is a United States Food and Drug Administration-approved drug used in the treatment of both solid tumor and lymphoid malignancies [1]. Pembrolizumab is an immune checkpoint inhibitor that inhibits the interaction between programmed death (PD-1) with its ligands PD-L1 and PD-L2, thereby leading to cytotoxic T cell-mediated cancer cell recognition and anti-tumor activity [1]. Regarding adverse reactions, it can affect any organ system, with the skin being one of the most commonly affected organs [2]. The cutaneous side effects can range from mild maculopapular rash to life-threatening Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [2].

Case Presentation
A 49-year-old male with no significant past medical history except for 14-year smoking history was evaluated for three months of shortness of breath. Imaging modalities including CT Chest and positron emission tomography (PET) scan revealed a right mediastinal lung mass of 3.4 x 4.1 cm, right-sided pleural effusion, and multiple mediastinal and hilar lymphadenopathy (Figure 1). Pathology of the lung mass biopsy showed poorly differentiated non-small cell lung cancer (NSCLC). Pleural fluid cytology was also positive for poorly differentiated NSCLC. The molecular markers tested positive for 100% PD-L1, but negative for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, and receptor tyrosine kinase (ROS-1).
His clinical course was complicated by recurrent pleural effusions, requiring multiple thoracenteses in two weeks. He was started on a combination of chemotherapy and immunotherapy with carboplatin, paclitaxel, and pembrolizumab (Keytruda®, Merck & Co., Inc., Rahway, USA). Unfortunately following the first cycle of the combination chemotherapy, he developed diffuse maculopapular skin rash involving >95% of the body surface area (Figures 2–6). Mucous membranes were not involved. The rash was not exfoliative in nature but was associated with pruritus. These rashes were considered to be an immune-related adverse reaction from the pembrolizumab. Hence, he was started on a low dose of 10 mg prednisone.
FIGURE 2: Diffuse maculopapular rash involving the trunk and back.
FIGURE 3: Diffuse maculopapular rash involving the chest and abdomen.
FIGURE 4: Diffuse maculopapular rash involving the posterior aspect of bilateral lower extremities.
FIGURE 5: Maculopapular rash involving the right foot and toes.
FIGURE 6: Diffuse maculopapular rash involving the anterolateral aspect of right thigh and knee.

The patient showed excellent clinical response after the first cycle of chemotherapy-immunotherapy combination. His shortness of breath was dramatically improved and did not require any further thoracentesis. As the tumor had 100% expression of PD-L1, and the patient showed excellent clinical response, the decision was made to continue with the chemo-immunotherapy combination, along with 10 mg of prednisone for the prophylaxis of immune-related adverse reaction. Following the second cycle, he developed significant neuropathy in bilateral lower extremities, and hence carboplatin and paclitaxel were discontinued. However, he was continued on single-agent pembrolizumab, along with 10 mg of prednisone as mentioned above.

The rashes started to resolve with the steroids. Interestingly he did not develop any further rash after the fourth dose of pembrolizumab and eventually prednisone was tapered off. The patient continues to be on pembrolizumab maintenance therapy, without any steroids.

Discussion
Lung cancer is the second most commonly diagnosed cancer after breast cancer and is the leading cause of cancer-related death in the world [3]. Non-small cell lung cancer accounts for more than 80-85% of lung cancer cases [4]. More than 60% of lung cancer patients present with locally advanced or metastatic disease at diagnosis [4]. Platinum-based chemotherapy remained the standard of care for metastatic non-small cell lung cancer (NSCLC) before the development of immune checkpoint inhibitors [1].

PD-L1 (programmed cell death ligand 1) is an immunoregulatory molecule that inhibits the cytotoxic CD8 T-cell activity, following the interaction with its PD-1 receptor [5]. Pembrolizumab is a humanized monoclonal IgG4 antibody that disrupts this interaction between PD-1 and PD-L1, thus leading to the recognition of cancer cells by the cytotoxic CD8 T-cells. In October 2016, FDA approved the use of pembrolizumab for previously untreated metastatic NSCLC with >50% PD-L1 expression, and for metastatic NSCLC with >1% PD-L1 expression who has progressed on platinum-based chemotherapy [1]. The addition of pembrolizumab to platinum-based chemotherapy in previously untreated metastatic NSCLC without EGF R or ALK mutations has shown to have longer overall survival and progression-free survival than chemotherapy alone [6].

Pembrolizumab is associated with a wide range of adverse events referred to as immune-related adverse events (ir-AEs). These include hepatitis, colitis, pneumonitis, hypothyroidism, and cutaneous adverse events [7]. These adverse events are believed to be due to the lack of inhibition of T-cells [8]. The cutaneous adverse effects can affect the quality of life of the patients and can result in dose reduction or even discontinuation of the treatment [2,9]. The time of onset of the cutaneous toxicities can range from 4 to 10 months from the initiation of the treatment [10].

The overall cutaneous toxicities related to anti-PD1 antibodies are reported to be as high as 49% [11]. It can range from a mild rash to life-threatening toxic epidermal necrolysis (TEN) [12]. The three most commonly reported cutaneous adverse events related to anti-PD-L1 therapy include skin rash not otherwise specified, pruritus, and vitiligo [13, 14]. These cutaneous adverse events usually increase with increasing exposure to the treatment and thus require long-term monitoring [11]. A study by Sanlorenzo, M et al. investigated the development of cutaneous adverse events in a cohort of 83 patients treated with pembrolizumab [9]. In this study, maculopapular eruptions were the most common cutaneous reaction (occurring in up to 29%) and developed following the first dose of the pembrolizumab. None of these patients had mucous membrane involvement.

The cutaneous and mucocutaneous adverse events associated with PD-L1 inhibitors usually respond to topical and systemic steroids [9]. A single-institution study conducted by Coleman, E et al. investigated the dermatological adverse events associated with immune checkpoint inhibitors and their response to treatment [15]. Ninety-eight patients were included in the study, out of which 25% developed lichenoid reactions, 18% developed maculopapular or exanthematous reactions, and 17% developed psoriatic reactions. Seventy-five percent of the lesions had associated pruritus. Ninety percent of the rashes responded to topical steroids, while 20% required systemic steroids. A small percentage of the study population developed severe adverse reactions including immunobullous reactions, Stevens-Johnson syndrome, and erythroderma. They required aggressive treatment including acitretin, UVB (ultraviolet B) phototherapy, methotrexate, dapsone, and infliximab. Pruritus was managed with topical corticosteroids, topical camphor-menthol, antihistamines, gabapentin, pregabalin, and aprepitant. There was a temporary interruption of the treatment in 15.5% of the study population, and complete discontinuation in 8.7% of the population [15].

Another single-institution study of three cases of bullous lichen planus-like reaction following treatment with pembrolizumab was defined by Walkade DV [16]. Two patients had metastatic NSCLC and the third patient had metastatic melanoma. All of them had <95% of body surface area involved and resulted in interruption of treatment with pembrolizumab. There are other similar reported cases of adverse skin reactions including glossitis, bullous pemphigoid, and tumoral melanosis, treated with topical and systemic steroids, but resulted in disruption of treatment with pembrolizumab [17-20]. Our case is unique in the fact that he had >95% of body surface area involved, and pembrolizumab was never stopped.

Conclusions
Pembrolizumab is an immune checkpoint inhibitor against PD-L1 and is widely used in the treatment of lung cancer. Pembrolizumab has been associated with immune-related cutaneous adverse events. Early identification of these cutaneous adverse events is of extreme importance. However, not every case will require high-dose steroids, and/or interruption of therapy. Our patient required only a short course of low-dose steroids without interruption of treatment with pembrolizumab. Thus, it is important to recognize the variety of skin reactions, and differences in the treatment paradigm, so that it can help reduce unnecessary interruption of the immunotherapy.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In
compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Rihawi K, Gelsomino F, Sperandi F, Melotti B, Fiorentino M, Casolari L, Ardizzoni A: Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. Ther Adv Respir Dis. 2017, 11:553-73. 10.1177/1753466817725486

2. Collins LK, Chapman MS, Carter JB, Samie FH: Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017, 41:115-8. 10.1016/j.curprobcancer.2016.12.001

3. What is lung cancer? | Types of lung cancer . (2019). Accessed: June 21, 2022: https://www.cancer.org/cancer/lung-cancer/about/what-is.html.

4. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG: Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015, 10:1240-2. 10.1016/j.jto.2015.03.034

5. Osmani L, Askin F, Gabrielson E, Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018, 52:105-9. 10.1016/j.semcancer.2017.11.019

6. Gandhi L, Rodriguez-Aعبر D, Gadgeel S, et al.: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056/NEJMoa1801005

7. Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyer L, Korenstein D: Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k795. 10.1136/bmj.k795

8. Navarro-Pereyra C, Garcia-Gonzalez J, Perez-Blazquez E: Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab. Indian J Ophthalmol. 2019, 67:2075-7. 10.4103/ijo.IJO_1161_19

9. Sanlenerozo M, Vujic I, Daad A, et al.: Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015, 151:1206-12. 10.1001/jamadermatol.2015.1916

10. Shi VJ, Rodic N, Gettigner S, et al.: Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016, 152:1128-36. 10.1001/jamadermatol.2016.2226

11. Hwang SJ, Carlos G, Wakade D, et al.: Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016, 74:457-61.e1. 10.1016/j.jaad.2015.10.029

12. Hwang SJ, Fernández-Perias P: Adverse reactions to biologics: melanoma (ipilimumab, nivolumab, pembrolizumab). Curr Probl Dermatol. 2018, 53:82-92. 10.1159/000478081

13. Robert C, Schachter J, Long GV, et al.: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056/NEJMoa1505095

14. Beluns VR, Berhuri B, Postow MA, et al.: Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016, 60:12-25. 10.1016/j.ejca.2016.02.010

15. Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal IS: Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2018, 80:990-7. 10.1016/j.jaad.2018.10.062

16. Wakade DV, Carlos G, Hwang SJ, Chou S, Hui R, Fernandez-Perias P: PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Res. 2016, 26:421-4. 10.1097/CMR.0000000000000265

17. Alias A, Hall JA, Kulkarni P, Gowan AC: Pembrolizumab-induced immune-mediated glossitis. Cureus. 2022, 14:e21708. 10.7759/cureus.21708

18. Chatterjee T, Rashid TF, Syed SB, Roy M: Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report. Cureus. 2022, 14:e21770. 10.7759/cureus.21770

19. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Perias P: A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015, 25:265-8. 10.1097/CMR.0000000000000155

20. Bari O, Cohen PR: Tumoral melanosis associated with pembrolizumab-treated metastatic melanoma . Cureus. 2017, 9:e1026. 10.7759/cureus.1026